229 related articles for article (PubMed ID: 37345898)
1. YTHDF2/m
Zhang L; Dou X; Zheng Z; Ye C; Lu TX; Liang HL; Wang L; Weichselbaum RR; He C
EMBO J; 2023 Aug; 42(15):e113126. PubMed ID: 37345898
[TBL] [Abstract][Full Text] [Related]
2. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy.
Wang L; Dou X; Chen S; Yu X; Huang X; Zhang L; Chen Y; Wang J; Yang K; Bugno J; Pitroda S; Ding X; Piffko A; Si W; Chen C; Jiang H; Zhou B; Chmura SJ; Luo C; Liang HL; He C; Weichselbaum RR
Cancer Cell; 2023 Jul; 41(7):1294-1308.e8. PubMed ID: 37236197
[TBL] [Abstract][Full Text] [Related]
3. m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response.
Yu R; Li Q; Feng Z; Cai L; Xu Q
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875984
[TBL] [Abstract][Full Text] [Related]
4. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
5. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response.
Zhang L; Li Y; Zhou L; Zhou H; Ye L; Ou T; Hong H; Zheng S; Zhou Z; Wu K; Yan Z; Thiery JP; Cui J; Wu S
Cancer Res; 2023 Jun; 83(11):1834-1850. PubMed ID: 36939388
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8
Ma S; Sun B; Duan S; Han J; Barr T; Zhang J; Bissonnette MB; Kortylewski M; He C; Chen J; Caligiuri MA; Yu J
Nat Immunol; 2023 Feb; 24(2):255-266. PubMed ID: 36658237
[TBL] [Abstract][Full Text] [Related]
7. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
8. YTHDF2 Regulates Macrophage Polarization through NF-
Cai L; Li D; Feng Z; Gu X; Xu Q; Li Q
Dis Markers; 2022; 2022():3153362. PubMed ID: 36277978
[TBL] [Abstract][Full Text] [Related]
9. YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.
Wen J; Xue L; Wei Y; Liang J; Jia W; Yong T; Chu L; Li H; Han S; Liao J; Chen Z; Liu Y; Liu Q; Ding Z; Liang H; Gan L; Chen X; Huang Z; Zhang B
Adv Sci (Weinh); 2024 Apr; 11(13):e2307242. PubMed ID: 38247171
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.
Chuckran CA; Cillo AR; Moskovitz J; Overacre-Delgoffe A; Somasundaram AS; Shan F; Magnon GC; Kunning SR; Abecassis I; Zureikat AH; Luketich J; Pennathur A; Sembrat J; Rojas M; Merrick DT; Taylor SE; Orr B; Modugno F; Buckanovich R; Schoen RE; Kim S; Duvvuri U; Zeh H; Edwards R; Kirkwood JM; Coffman L; Ferris RL; Bruno TC; Vignali DAA
Sci Transl Med; 2021 Dec; 13(623):eabf8495. PubMed ID: 34878821
[TBL] [Abstract][Full Text] [Related]
11. YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-κB and MAPK signaling pathways.
Fang C; He M; Li D; Xu Q
Cell Signal; 2021 Sep; 85():110060. PubMed ID: 34089814
[TBL] [Abstract][Full Text] [Related]
12. Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner.
Fan T; Du Y; Zhang M; Zhu AR; Zhang J
Gerontology; 2022; 68(8):920-934. PubMed ID: 35468611
[TBL] [Abstract][Full Text] [Related]
13. m
Ruan P; Wang S; Yang C; Huang X; Sun P; Tan A
Cell Biol Toxicol; 2023 Aug; 39(4):1611-1626. PubMed ID: 35971034
[TBL] [Abstract][Full Text] [Related]
14. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
15. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
17. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
18. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
19. The tumor-intrinsic role of the m
Xiao S; Ma S; Sun B; Pu W; Duan S; Han J; Hong Y; Zhang J; Peng Y; He C; Yi P; Caligiuri MA; Yu J
Sci Immunol; 2024 May; 9(95):eadl2171. PubMed ID: 38820140
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
